Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Community analysis and co-occurrence patterns in airway microbial communities during health and disease.

Einarsson GG, Zhao J, LiPuma JJ, Downey DG, Tunney MM, Elborn JS.

ERJ Open Res. 2019 Jul 8;5(3). pii: 00128-2017. doi: 10.1183/23120541.00128-2017. eCollection 2019 Jul.

2.

Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis.

Sherrard LJ, Einarsson GG, Johnston E, O'Neill K, McIlreavey L, McGrath SJ, Gilpin DF, Downey DG, Reid A, McElvaney NG, Boucher RC, Muhlebach MS, Elborn JS, Tunney MM.

J Cyst Fibros. 2019 Mar 21. pii: S1569-1993(19)30052-9. doi: 10.1016/j.jcf.2019.02.012. [Epub ahead of print]

PMID:
30905581
3.

Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review.

Somayaji R, Parkins MD, Shah A, Martiniano SL, Tunney MM, Kahle JS, Waters VJ, Elborn JS, Bell SC, Flume PA, VanDevanter DR; Antimicrobial Resistance in Cystic Fibrosis InternationalWorking Group.

J Cyst Fibros. 2019 Mar;18(2):236-243. doi: 10.1016/j.jcf.2019.01.008. Epub 2019 Jan 30.

PMID:
30709744
4.

Interventions to Improve Antimicrobial Stewardship for Older People in Care Homes: A Systematic Review.

Nguyen HQ, Tunney MM, Hughes CM.

Drugs Aging. 2019 Apr;36(4):355-369. doi: 10.1007/s40266-019-00637-0.

PMID:
30675682
5.

The lung and gut microbiome: what has to be taken into consideration for cystic fibrosis?

Héry-Arnaud G, Boutin S, Cuthbertson L, Elborn SJ, Tunney MM.

J Cyst Fibros. 2019 Jan;18(1):13-21. doi: 10.1016/j.jcf.2018.11.003. Epub 2018 Nov 25. Review.

PMID:
30487080
6.

Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in Prevotella isolated from cystic fibrosis (CF) and non-CF patients.

Sherrard LJ, Schaible B, Graham KA, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, Muhlebach MS, Gilpin DF, Schneiders T, Stuart Elborn J, Tunney MM.

J Antimicrob Chemother. 2018 Nov 1;73(11):3218. doi: 10.1093/jac/dky313. No abstract available.

PMID:
30351435
7.

Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated from cystic fibrosis patients.

Díez-Aguilar M, Ekkelenkamp M, Morosini MI, Merino I, de Dios Caballero J, Jones M, van Westreenen M, Tunney MM, Cantón R, Fluit AC.

Int J Antimicrob Agents. 2019 Jan;53(1):84-88. doi: 10.1016/j.ijantimicag.2018.09.001. Epub 2018 Sep 19.

PMID:
30240837
8.

Activity of hypothiocyanite and lactoferrin (ALX-009) against respiratory cystic fibrosis pathogens in sputum.

Tunney MM, Payne JE, McGrath SJ, Einarsson GG, Ingram RJ, Gilpin DF, Juarez-Perez V, Elborn JS.

J Antimicrob Chemother. 2018 Dec 1;73(12):3391-3397. doi: 10.1093/jac/dky357.

PMID:
30219825
9.

Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study.

Muhlebach MS, Hatch JE, Einarsson GG, McGrath SJ, Gilipin DF, Lavelle G, Mirkovic B, Murray MA, McNally P, Gotman N, Davis Thomas S, Wolfgang MC, Gilligan PH, McElvaney NG, Elborn JS, Boucher RC, Tunney MM.

Eur Respir J. 2018 Jul 11;52(1). pii: 1800242. doi: 10.1183/13993003.00242-2018. Print 2018 Jul.

10.

Criteria required for an acceptable point-of-care test for UTI detection: Obtaining consensus using the Delphi technique.

Weir NM, Pattison SH, Kearney P, Stafford B, Gormley GJ, Crockard MA, Gilpin DF, Tunney MM, Hughes CM.

PLoS One. 2018 Jun 7;13(6):e0198595. doi: 10.1371/journal.pone.0198595. eCollection 2018.

11.

"Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.

Gilligan PH, Downey DG, Elborn JS, Flume PA, Funk S, Gilpin D, Kidd TJ, McCaughan J, Millar BC, Murphy PG, Rendall JC, Tunney MM, Moore JE.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e00193-18. doi: 10.1128/JCM.00193-18. Print 2018 Sep.

12.

Airway infection, systemic inflammation and lung clearance index in children and adults with cystic fibrosis.

O'Neill K, Bradley JM, Reid A, Downey DG, Rendall J, McCaughan J, Moore JE, Tunney MM, Elborn JS.

Eur Respir J. 2018 Jan 31;51(2). pii: 1701704. doi: 10.1183/13993003.01704-2017. Print 2018 Feb. No abstract available.

PMID:
29386349
13.

CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor.

Ronan NJ, Einarsson GG, Twomey M, Mooney D, Mullane D, NiChroinin M, O'Callaghan G, Shanahan F, Murphy DM, O'Connor OJ, Shortt CA, Tunney MM, Eustace JA, Maher MM, Elborn JS, Plant BJ.

Chest. 2018 Feb;153(2):395-403. doi: 10.1016/j.chest.2017.10.005. Epub 2017 Oct 14.

PMID:
29037527
14.

Novel freeze-dried DDA and TPGS liposomes are suitable for nasal delivery of vaccine.

Yusuf H, Ali AA, Orr N, Tunney MM, McCarthy HO, Kett VL.

Int J Pharm. 2017 Nov 25;533(1):179-186. doi: 10.1016/j.ijpharm.2017.09.011. Epub 2017 Sep 6.

PMID:
28887219
15.

Training in multiple breath washout testing for respiratory physiotherapists.

O'Neill K, Elborn JS, Tunney MM, O'Neill P, Rowan S, Martin S, Bradley JM.

Physiotherapy. 2018 Mar;104(1):61-66. doi: 10.1016/j.physio.2017.04.003. Epub 2017 Apr 25.

PMID:
28822601
16.

Proteomic profile of cystic fibrosis sputum cells in adults chronically infected with Pseudomonas aeruginosa.

Pattison SH, Gibson DS, Johnston E, Peacock S, Rivera K, Tunney MM, Pappin DJ, Elborn JS.

Eur Respir J. 2017 Jul 5;50(1). pii: 1601569. doi: 10.1183/13993003.01569-2016. Print 2017 Jul.

17.

Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens.

Payne JE, Dubois AV, Ingram RJ, Weldon S, Taggart CC, Elborn JS, Tunney MM.

Int J Antimicrob Agents. 2017 Sep;50(3):427-435. doi: 10.1016/j.ijantimicag.2017.04.014. Epub 2017 Jun 27.

PMID:
28666755
18.

Evidence of persistence of Prevotella spp. in the cystic fibrosis lung.

Gilpin DF, Nixon KA, Bull M, McGrath SJ, Sherrard L, Rolain JM, Mahenthiralingam E, Elborn JS, Tunney MM.

J Med Microbiol. 2017 Jun 13. doi: 10.1099/jmm.0.000500. [Epub ahead of print]

PMID:
28604331
19.

Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients.

Mustafa MH, Khandekar S, Tunney MM, Elborn JS, Kahl BC, Denis O, Plésiat P, Traore H, Tulkens PM, Vanderbist F, Van Bambeke F.

Eur Respir J. 2017 May 19;49(5). pii: 1601847. doi: 10.1183/13993003.01847-2016. Print 2017 May.

20.

Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis.

Vallières E, Tumelty K, Tunney MM, Hannah R, Hewitt O, Elborn JS, Downey DG.

Eur Respir J. 2017 Apr 12;49(4). pii: 1600851. doi: 10.1183/13993003.00851-2016. Print 2017 Apr. No abstract available.

21.

Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study.

O'Neill K, Moran F, Tunney MM, Elborn JS, Bradbury I, Downey DG, Rendall J, Bradley JM.

BMJ Open Respir Res. 2017 Jan 12;4(1):e000168. doi: 10.1136/bmjresp-2016-000168. eCollection 2017.

22.

Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic.

Chalhoub H, Pletzer D, Weingart H, Braun Y, Tunney MM, Elborn JS, Rodriguez-Villalobos H, Plésiat P, Kahl BC, Denis O, Winterhalter M, Tulkens PM, Van Bambeke F.

Sci Rep. 2017 Jan 16;7:40208. doi: 10.1038/srep40208.

23.

Response.

O'Neill K, Elborn JS, Tunney MM, Bradley JM.

Chest. 2016 Dec;150(6):1413-1414. doi: 10.1016/j.chest.2016.09.037. No abstract available.

PMID:
27938757
24.

Corrigendum to 'Efficacy of a standard meticillin-resistant Staphylococcus aureus decolonisation protocol in routine clinical practice' [Journal of Hospital Infection (2010) 93-98].

Gilpin DF, Small S, Bakshi S, Kearney MP, Cardwell C, Tunney MM.

J Hosp Infect. 2016 Dec;94(4):411. doi: 10.1016/j.jhin.2016.07.018. Epub 2016 Oct 19. No abstract available.

PMID:
27771148
25.

MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis.

Vallières E, Rendall JC, Moore JE, McCaughan J, Hoeritzauer AI, Tunney MM, Elborn JS, Downey DG.

ERJ Open Res. 2016 Mar 15;2(1). pii: 00064-2015. eCollection 2016 Jan.

26.

Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.

Mustafa MH, Chalhoub H, Denis O, Deplano A, Vergison A, Rodriguez-Villalobos H, Tunney MM, Elborn JS, Kahl BC, Traore H, Vanderbist F, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6735-6741. doi: 10.1128/AAC.01046-16. Print 2016 Nov.

27.

The role of anaerobic bacteria in the cystic fibrosis airway.

Sherrard LJ, Bell SC, Tunney MM.

Curr Opin Pulm Med. 2016 Nov;22(6):637-43. doi: 10.1097/MCP.0000000000000299. Review.

PMID:
27455453
28.

Lung Clearance Index in Adults and Children With Cystic Fibrosis.

O'Neill K, Tunney MM, Johnston E, Rowan S, Downey DG, Rendall J, Reid A, Bradbury I, Elborn JS, Bradley JM.

Chest. 2016 Dec;150(6):1323-1332. doi: 10.1016/j.chest.2016.06.029. Epub 2016 Jul 6.

PMID:
27395423
29.

Eradication and phenotypic tolerance of Burkholderia cenocepacia biofilms exposed to atmospheric pressure non-thermal plasma.

Alshraiedeh NH, Higginbotham S, Flynn PB, Alkawareek MY, Tunney MM, Gorman SP, Graham WG, Gilmore BF.

Int J Antimicrob Agents. 2016 Jun;47(6):446-50. doi: 10.1016/j.ijantimicag.2016.03.004. Epub 2016 Apr 22.

PMID:
27179816
30.

Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers.

Einarsson GG, Comer DM, McIlreavey L, Parkhill J, Ennis M, Tunney MM, Elborn JS.

Thorax. 2016 Sep;71(9):795-803. doi: 10.1136/thoraxjnl-2015-207235. Epub 2016 May 4.

PMID:
27146202
31.

Production of extended-spectrum β-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota.

Sherrard LJ, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, Muhlebach MS, Gilpin DF, Elborn JS, Tunney MM.

Int J Antimicrob Agents. 2016 Feb;47(2):140-5. doi: 10.1016/j.ijantimicag.2015.12.004. Epub 2015 Dec 29.

32.

Lack of Association Between Haptoglobin Phenotype and Cystic Fibrosis Outcomes.

Shteinberg M, Rivlin J, Gur M, Konopnicki M, Stein N, Tunney MM, Elborn JS, Downey DG, Johnston E, Shalom H, Levy A.

Lung. 2015 Dec;193(6):1017-21. doi: 10.1007/s00408-015-9801-z. Epub 2015 Sep 14.

PMID:
26370551
33.

The Role of Short-Chain Fatty Acids, Produced by Anaerobic Bacteria, in the Cystic Fibrosis Airway.

Mirković B, Murray MA, Lavelle GM, Molloy K, Azim AA, Gunaratnam C, Healy F, Slattery D, McNally P, Hatch J, Wolfgang M, Tunney MM, Muhlebach MS, Devery R, Greene CM, McElvaney NG.

Am J Respir Crit Care Med. 2015 Dec 1;192(11):1314-24. doi: 10.1164/rccm.201505-0943OC.

34.

Reduced bacterial colony count of anaerobic bacteria is associated with a worsening in lung clearance index and inflammation in cystic fibrosis.

O'Neill K, Bradley JM, Johnston E, McGrath S, McIlreavey L, Rowan S, Reid A, Bradbury I, Einarsson G, Elborn JS, Tunney MM.

PLoS One. 2015 May 20;10(5):e0126980. doi: 10.1371/journal.pone.0126980. eCollection 2015.

35.

Predictors of adherence to treatment in bronchiectasis.

McCullough AR, Tunney MM, Stuart Elborn J, Bradley JM, Hughes CM.

Respir Med. 2015 Jul;109(7):838-45. doi: 10.1016/j.rmed.2015.04.011. Epub 2015 Apr 25.

36.

Microbiology review series: CF microbiology - -Towards 2020 and beyond.

Rogers GB, Tunney MM.

J Cyst Fibros. 2015 May;14(3):289-90. doi: 10.1016/j.jcf.2015.03.016. Epub 2015 Apr 12. No abstract available.

37.

Comparison of microbiomes from different niches of upper and lower airways in children and adolescents with cystic fibrosis.

Boutin S, Graeber SY, Weitnauer M, Panitz J, Stahl M, Clausznitzer D, Kaderali L, Einarsson G, Tunney MM, Elborn JS, Mall MA, Dalpke AH.

PLoS One. 2015 Jan 28;10(1):e0116029. doi: 10.1371/journal.pone.0116029. eCollection 2015.

38.

Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis.

Sherrard LJ, Tunney MM, Elborn JS.

Lancet. 2014 Aug 23;384(9944):703-13. doi: 10.1016/S0140-6736(14)61137-5. Review.

PMID:
25152272
39.

Treatment adherence and health outcomes in patients with bronchiectasis.

McCullough AR, Tunney MM, Quittner AL, Elborn JS, Bradley JM, Hughes CM.

BMC Pulm Med. 2014 Jul 1;14:107. doi: 10.1186/1471-2466-14-107.

40.

'All illness is personal to that individual': a qualitative study of patients' perspectives on treatment adherence in bronchiectasis.

McCullough AR, Tunney MM, Elborn JS, Bradley JM, Hughes CM.

Health Expect. 2015 Dec;18(6):2477-88. doi: 10.1111/hex.12217. Epub 2014 Jun 20.

41.

Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in Prevotella isolated from cystic fibrosis (CF) and non-CF patients.

Sherrard LJ, Schaible B, Graham KA, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, Muhlebach MS, Gilpin DF, Schneiders T, Elborn JS, Tunney MM.

J Antimicrob Chemother. 2014 Oct;69(10):2690-8. doi: 10.1093/jac/dku192. Epub 2014 Jun 10.

42.

BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs.

Döring G, Bragonzi A, Paroni M, Aktürk FF, Cigana C, Schmidt A, Gilpin D, Heyder S, Born T, Smaczny C, Kohlhäufl M, Wagner TO, Loebinger MR, Bilton D, Tunney MM, Elborn JS, Pier GB, Konstan MW, Ulrich M.

J Cyst Fibros. 2014 Mar;13(2):156-63. doi: 10.1016/j.jcf.2013.10.007. Epub 2013 Oct 31.

43.

The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection.

McCaughey G, Gilpin D, Elborn J, Tunney MM.

Expert Rev Respir Med. 2013 Aug;7(4):385-96. doi: 10.1586/17476348.2013.814411. Review.

PMID:
23964628
44.

Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.

McCaughey G, Gilpin DF, Schneiders T, Hoffman LR, McKevitt M, Elborn JS, Tunney MM.

Antimicrob Agents Chemother. 2013 Nov;57(11):5406-14. doi: 10.1128/AAC.00750-13. Epub 2013 Aug 19.

45.

Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.

McCaughey G, Diamond P, Elborn JS, McKevitt M, Tunney MM.

PLoS One. 2013 Jul 25;8(7):e69763. doi: 10.1371/journal.pone.0069763. Print 2013.

46.

Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis.

Moffitt KL, Martin SL, Jones AM, Webb AK, Cardwell C, Tunney MM, Elborn JS.

J Cyst Fibros. 2014 Jan;13(1):63-8. doi: 10.1016/j.jcf.2013.06.002. Epub 2013 Jul 13.

47.

Antibiotic resistance in Prevotella species isolated from patients with cystic fibrosis.

Sherrard LJ, Graham KA, McGrath SJ, McIlreavey L, Hatch J, Muhlebach MS, Wolfgang MC, Gilpin DF, Elborn JS, Schneiders T, Tunney MM.

J Antimicrob Chemother. 2013 Oct;68(10):2369-74. doi: 10.1093/jac/dkt191. Epub 2013 May 21.

48.

Improving prescribing of antibiotics in long-term care: resistant to change?

Hughes CM, Tunney MM.

JAMA Intern Med. 2013 Apr 22;173(8):682-3; discussion 683. doi: 10.1001/jamainternmed.2013.4077. No abstract available.

PMID:
23553011
49.

Macrolides and bronchiectasis: clinical benefit with a resistance price.

Elborn JS, Tunney MM.

JAMA. 2013 Mar 27;309(12):1295-6. doi: 10.1001/jama.2013.2780. No abstract available.

PMID:
23532247
50.

Molecular detection of CF lung pathogens: current status and future potential.

Pattison SH, Rogers GB, Crockard M, Elborn JS, Tunney MM.

J Cyst Fibros. 2013 May;12(3):194-205. doi: 10.1016/j.jcf.2013.01.007. Epub 2013 Feb 10. Review.

Supplemental Content

Loading ...
Support Center